Pharmacy

Impel Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Friday, March 24, 2023
Migraine, IPO, SG, Pharmacy, Marketing, Bank statement, AAN, IMPL, Headache (journal), AHS, Prescription, American Academy, GAAP, DHE, R, The Journal of Headache and Pain, Journal, Patient, Administration, Manuscript, Host, Otorhinolaryngology, Webcast, Growth, Research and development, American Academy of Neurology, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Conference, Food, Safety, Video game, Cryptocurrency, Pharmaceutical industry, Health insurance, Headache, Dihydroergotamine, Pain, Q4, Impeller

SEATTLE, March 24, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.

Key Points: 
  • ET
    SEATTLE, March 24, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.
  • New Trudhesa prescriptions increased by 24 percent from Q3 to Q4 2022 driven by an expanded, more efficient salesforce.
  • Reimbursement of all shipments is 60 percent for the fourth quarter 2022.
  • ET today to discuss the fourth quarter and full year 2022 financial results and provide a corporate and business update.

Meituan Announces Financial Results for the Year Ended December 31, 2022

Retrieved on: 
Friday, March 24, 2023
Operating cost, Treasury, Food delivery, Employment, Travel, Depression, Habit, Snack, Marketing, Pharmacy, Electronics, Personal protective equipment, World cup, Farmer, Perception, COVID-19, Core, Meal, Stock, Medicine, COVID, Occupational injury, EBITDA, Beauty, Acquisition, Top-line growth, City, GTV, Ecosystem, Growth, HKG, Safety, Cryptocurrency, Retail, Video game, Online shopping, Tourism

Meanwhile, the operating loss for our New initiatives segment narrowed to RMB28.4 billion in 2022 from RMB35.9 billion in 2021.

Key Points: 
  • Meanwhile, the operating loss for our New initiatives segment narrowed to RMB28.4 billion in 2022 from RMB35.9 billion in 2021.
  • We held cash and cash equivalents of RMB20.2 billion and short-term treasury investments of RMB91.9 billion as of December 31, 2022.
  • In 2022, we achieved 17.6% revenue growth for the Core local commerce segment, despite negative impacts from the macro environment.
  • Our food delivery business posted steady, high-quality growth in 2022, with peak daily order volume surpassing 60 million.

Three Leading Cancer Centers Awarded Medically Integrated Pharmacy Accreditation

Retrieved on: 
Thursday, March 23, 2023
University of Florida Cancer and Genetics Research Complex, Pharmacy, Doctor of Pharmacy, Accreditation, COE, Hematology, Quality, European Hematology Association, Patient, ACHC, URAC, Nursing, Rx

CAZENOVIA, N.Y., March 23, 2023 /PRNewswire/ -- Three leading medically integrated oncology practices were awarded NCODA's Center of Excellence Medically Integrated Pharmacy Accreditation at the NCODA International Spring Forum that took place on March 15 – 17, 2023 in Indianapolis, IN.

Key Points: 
  • CAZENOVIA, N.Y., March 23, 2023 /PRNewswire/ -- Three leading medically integrated oncology practices were awarded NCODA's Center of Excellence Medically Integrated Pharmacy Accreditation at the NCODA International Spring Forum that took place on March 15 – 17, 2023 in Indianapolis, IN.
  • The only accreditation program designed specifically for medically integrated practices.
  • This three-year accreditation, based on compliance with the ASCO/NCODA Patient-Centered Standards for Medically Integrated Dispensing is the only accreditation program designed specifically for medically integrated practices.
  • These new offerings allow medically integrated pharmacies servicing multiple disease states to benefit from a patient-centered accreditation program without the presence of administrative burdens.

Hospital Logistics Robots Global Market Report 2023: Rising Need for Remote Care Fuels Sector Growth

Retrieved on: 
Thursday, March 23, 2023
Learning, ABB, Telehealth, Natural language processing, Communication, Aethon, Teradyne, Internet of things, ML, Research, Pharmacy, USD, NLP, Row, Patient, Application, Machine learning, AGV, Fourth Industrial Revolution, Artificial intelligence, Speciality chemicals, Medical device

DUBLIN, March 23, 2023 /PRNewswire/ -- The "Hospital Logistics Robots Market by Type and Application - Global Opportunity Analysis and Industry Forecast 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 23, 2023 /PRNewswire/ -- The "Hospital Logistics Robots Market by Type and Application - Global Opportunity Analysis and Industry Forecast 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • Demand for hospital logistics robots has increased across the globe, owing to rise in need for remote care, such as telemedicine and telehealth.
  • The global hospital logistics robots market is segmented on the basis of type, application, and region.
  • The region dominates the hospital logistics robots market and is potently expected to remain dominant throughout the forecast period.

Cegedim: Full year 2022 results

Retrieved on: 
Thursday, March 23, 2023
Insurance, Marketing, Centre Hospitalier Universitaire Grenoble Alpes, Absenteeism, Lawyer, United States Court of Appeals for the Ninth Circuit, HGL, Audit committee, Acquisition, COVID-19, Collection, Investment, Risk, BPO, Automation, Software, Telehealth, Advertising, Pharmacy, PRO, IMS Health, IMS, Corporation, Growth, Data & Marketing Association, Personal Software Services, Webcast, Software as a service, Partnership, Bank statement, Sale, Typesetting, Music, Pharmaceutical industry, Risk management, Cryptocurrency, Video game, Life insurance, Groupe Casino, IQVIA, Cegedim, Ekaterina Sedia

Corporate and others: 2022 REBIT(1) was a €3.4 million loss, €2.3 million higher than the loss in 2021.

Key Points: 
  • Corporate and others: 2022 REBIT(1) was a €3.4 million loss, €2.3 million higher than the loss in 2021.
  • To the best of the company’s knowledge, there were no events or changes during 2022 that would materially alter the Group’s financial situation.
  • On May 16, 2022, Cegedim Group and social protection companies Malakoff Humanis, Groupe VYV, and PRO BTP Groupe announced that they had finalized the strategic partnership they began negotiating on March 1, 2022.
  • The webcast is available at: www.cegedim.fr/webcast
    The fiscal 2022 results presentation is available:
    And on the Cegedim IR smartphone app, available at https://www.cegedim.fr/finance/profil/Pages/CegedimIR.aspx

eTrueNorth and Hy-Vee, Inc. Partner to Offer Pharmacy-Based COVID-19 and Flu Test and Treat

Retrieved on: 
Thursday, March 23, 2023
Infection, Partnership, University, U.S. Department of Defense Strategy for Operating in Cyberspace, HHS, HIV, Washington State University, Pharmacy, Cholesterol, Office of Inspector General, U.S. Department of Health and Human Services, COVID-19, Hepatitis C, CDC, RSV, ICATT, Pharmaceutical industry, Sand, Vaccine

The newly available diagnostic test detects active COVID-19 and/or flu infection, with results available in as few as 30 minutes.

Key Points: 
  • The newly available diagnostic test detects active COVID-19 and/or flu infection, with results available in as few as 30 minutes.
  • Together, these two companies bring the test to treat service to a first wave of nine Hy-Vee pharmacies throughout Iowa until April 30, 2023.
  • "Rapid combination test results coupled with pharmacist-prescribed treatment at community pharmacies are solutions eTrueNorth is supporting for our pharmacy partners."
  • Part of the eTrueNorth mission is to increase the availability of point of care testing which offer results during the same visit.

Avricore Health’s HealthTab™ Passes 530 Locations, Adds Virus Detection

Retrieved on: 
Thursday, March 23, 2023
Pharmacy, Diabetes, Infection, CAD, ID, Shoppers Drug Mart, POCT, Pharmacist, Prediabetes, Patient, Point-of-care testing, Nursing, Pharmaceutical industry

In 100 of these locations, the Company will be deploying Abbott’s ID Now™, either in combination with the Afinion 2™ or standalone, to support virus detection and assess the demand and effectiveness of infectious disease screening in community pharmacies.

Key Points: 
  • In 100 of these locations, the Company will be deploying Abbott’s ID Now™, either in combination with the Afinion 2™ or standalone, to support virus detection and assess the demand and effectiveness of infectious disease screening in community pharmacies.
  • Supporting this change have been regulatory changes to expand the scope of practice of the pharmacist to diagnose and treat minor ailments.
  • The 10-year funding agreement being finalized between the federal and provincial governments ( source ), is anticipated to add necessary funds to support these new areas of work.
  • ( Source )
    There are more that 10,000 pharmacies in Canada, 88,000 pharmacies in the US, nearly 12,000 in the UK.

Military Families Share Why Living on Base is Best

Retrieved on: 
Thursday, March 23, 2023
Defense, Military, Other Construction & Property, Other Defense, Construction & Property, Orthodontics, Permanent, Housing, Health, Army, Soldier, Pest control, Pharmacy, United States Department of Defense, Multimedia, ID, United States Army, School, Dentist, United States Department of the Army, Work, Chamblee, Georgia, Water, Region, Family, Library, Daniele Corvia

View the full release here: https://www.businesswire.com/news/home/20230323005202/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230323005202/en/
    This list from the US Army highlights the additional benefits provided to soldiers and their families when they live on base.
  • (Graphic: Business Wire)
    According to the U.S. Army , “Living on base offers more than housing.
  • Active-duty military families never have to provide a security deposit or go through a credit check, which saves hundreds of dollars.
  • By living on a military installation, residents are surrounded by neighbors who understand the demands and nuances of military life.

Flume Health Launches Flume Relay To Speed Solution Integration

Retrieved on: 
Thursday, March 23, 2023
Conditional sentence, Health, Relay, TPA, Pharmacy, Self-funded health care, Engineering, Health insurance, Health care, Flume

Flume Relay aims to solve payers' greatest limitation: the integrations and real-time data exchange with the plethora of vendors and systems that make up a health plan.

Key Points: 
  • Flume Relay aims to solve payers' greatest limitation: the integrations and real-time data exchange with the plethora of vendors and systems that make up a health plan.
  • The inspiration for Flume Relay originated from Flume's engineering team, which initially created Relay in-house to easily connect and manage the hundreds of integrations related to health plan administration.
  • "Flume Relay alleviates this expensive burden and will allow payers to launch their next generation customized & personalized health plans, profitably."
  • Flume currently works with Firefly Health, Radion Health, Self Fund Health, and more.

Harm Reduction Therapeutics and Catalent Sign Commercial Supply Agreement for Naloxone Nasal Spray to Reverse Opioid Overdoses

Retrieved on: 
Thursday, March 23, 2023
Emergency, Doctor of Philosophy, Naloxone, Baltimore City Health Department, New Drug Application, Pharmacy, Harm reduction, Patient, OTC, Entrepreneurship, Nasal spray, Catalent, FDA, Therapy, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Health department, Pharmaceutical industry

PITTSBURGH, PA and SOMERSET, N.J., March 23, 2023 /PRNewswire-PRWeb/ -- Harm Reduction Therapeutics, a 501(c)(3) non-profit pharmaceutical company whose mission is to prevent opioid overdose deaths by making low-cost naloxone available to everyone, and Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced the signing of a commercial supply agreement. Under its terms, Catalent will manufacture Harm Reduction Therapeutics' naloxone nasal spray, RiVive™ (3.0 mg), for the emergency treatment of known or suspected opioid overdose.

Key Points: 
  • Under its terms, Catalent will manufacture Harm Reduction Therapeutics' naloxone nasal spray, RiVive™ (3.0 mg), for the emergency treatment of known or suspected opioid overdose.
  • PITTSBURGH, PA and SOMERSET, N.J., March 23, 2023 /PRNewswire-PRWeb/ -- Harm Reduction Therapeutics, a 501(c)(3) non-profit pharmaceutical company whose mission is to prevent opioid overdose deaths by making low-cost naloxone available to everyone, and Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced the signing of a commercial supply agreement.
  • Under its terms, Catalent will manufacture Harm Reduction Therapeutics' naloxone nasal spray, RiVive™ (3.0 mg), for the emergency treatment of known or suspected opioid overdose.
  • The commercial supply agreement comes after the U.S. Food and Drug Administration (FDA) granted Harm Reduction Therapeutics Priority Review status on December 26, 2022, for its over-the-counter (OTC) naloxone nasal spray New Drug Application.